Mn Services Vermogensbeheer B.V. Gilead Sciences, Inc. Transaction History

Mn Services Vermogensbeheer B.V.

$14.3 Billion
Q3 2024

A detailed history of Mn Services Vermogensbeheer B.V. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Mn Services Vermogensbeheer B.V. holds 480,855 shares of GILD stock, worth $45.2 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

480,855

Previous 492,755 2.41%

Holding current value

$45.2 Million

Previous $33.8 Million 19.25%

% of portfolio

0.28%

Previous 0.24%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	SELL	$66.59 - $83.99 $792,421 - $999,480	-11,900 Reduced 2.41%	480,855 $40.3 Million
Q2 2024 Jul 25, 2024	SELL	$63.15 - $72.88 $700,965 - $808,968	-11,100 Reduced 2.2%	492,755 $33.8 Million
Q1 2024 Apr 29, 2024	SELL	$71.58 - $87.29 $6.28 Million - $7.66 Million	-87,800 Reduced 14.84%	503,855 $36.9 Million
Q4 2023 Jan 29, 2024	SELL	$73.27 - $83.09 $1.38 Million - $1.57 Million	-18,900 Reduced 3.1%	591,655 $47.9 Million
Q3 2023 Oct 25, 2023	BUY	$73.94 - $80.67 $805,946 - $879,303	10,900 Added 1.82%	610,555 $45.8 Million
Q2 2023 Aug 09, 2023	SELL	$76.01 - $86.7 $1.9 Million - $2.17 Million	-25,000 Reduced 4.0%	599,655 $46.2 Million
Q1 2023 Apr 26, 2023	BUY	$77.31 - $88.08 $1.46 Million - $1.66 Million	18,900 Added 3.12%	624,655 $51.8 Million
Q4 2022 Feb 03, 2023	SELL	$62.32 - $89.47 $5.68 Million - $8.16 Million	-91,200 Reduced 13.09%	605,755 $52 Million
Q3 2022 Nov 01, 2022	SELL	$59.54 - $68.01 $2.39 Million - $2.73 Million	-40,100 Reduced 5.44%	696,955 $43 Million
Q2 2022 Aug 03, 2022	SELL	$57.72 - $65.01 $9.5 Million - $10.7 Million	-164,600 Reduced 18.26%	737,055 $45.6 Million
Q1 2022 May 10, 2022	SELL	$57.92 - $72.58 $3.33 Million - $4.17 Million	-57,500 Reduced 5.99%	901,655 $53.6 Million
Q4 2021 Feb 10, 2022	BUY	$64.88 - $73.64 $1.15 Million - $1.31 Million	17,800 Added 1.89%	959,155 $69.6 Million
Q3 2021 Nov 03, 2021	BUY	$67.69 - $73.03 $1.35 Million - $1.45 Million	19,900 Added 2.16%	941,355 $65.8 Million
Q2 2021 Aug 05, 2021	SELL	$63.47 - $69.35 $12 Million - $13.2 Million	-189,800 Reduced 17.08%	921,455 $53.5 Million
Q4 2020 Feb 09, 2021	BUY	$56.65 - $64.55 $725,120 - $826,240	12,800 Added 1.17%	1,111,255 $64.7 Million
Q3 2020 Nov 04, 2020	BUY	$62.1 - $78.08 $1.34 Million - $1.69 Million	21,600 Added 2.01%	1,098,455 $69.4 Million
Q2 2020 Jul 23, 2020	SELL	$72.34 - $84.0 $1.14 Million - $1.33 Million	-15,800 Reduced 1.45%	1,076,855 $82.9 Million
Q1 2020 May 12, 2020	SELL	$62.63 - $80.22 $4.3 Million - $5.51 Million	-68,700 Reduced 5.92%	1,092,655 $81.7 Million
Q4 2019 Feb 12, 2020	BUY	$61.62 - $67.78 $2.26 Million - $2.49 Million	36,700 Added 3.26%	1,161,355 $75.5 Million
Q3 2019 Nov 12, 2019	BUY	$62.51 - $69.0 $29.5 Million - $32.5 Million	471,725 Added 72.25%	1,124,655 $71.3 Million
Q2 2019 Jul 25, 2019	SELL	$61.87 - $69.38 $4.21 Million - $4.72 Million	-68,000 Reduced 9.43%	652,930 $44.1 Million
Q1 2019 May 06, 2019	BUY	$62.53 - $70.05 $406,445 - $455,325	6,500 Added 0.91%	720,930 $46.9 Million
Q4 2018 Feb 12, 2019	BUY	$60.54 - $79.0 $30.6 Million - $40 Million	505,855 Added 242.53%	714,430 $39.1 Million
Q3 2018 Nov 02, 2018	SELL	$71.28 - $78.92 $49,896 - $55,244	-700 Reduced 0.33%	208,575 $16.1 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $240,055 - $280,016	3,700 Added 1.8%	209,275 $14.8 Million
Q1 2018 May 11, 2018	BUY	$72.84 - $88.8 $167,532 - $204,240	2,300 Added 1.13%	205,575 $15.5 Million
Q4 2017 Feb 02, 2018	SELL	$71.15 - $83.52 $868,030 - $1.02 Million	-12,200 Reduced 5.66%	203,275 $12.1 Million
Q3 2017 Nov 01, 2017	BUY	$72.11 - $85.47 $15.5 Million - $18.4 Million	215,475	215,475 $17.5 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mn Services Vermogensbeheer B.V., based on Form 13F filings with the SEC.

News

Stay updated on Mn Services Vermogensbeheer B.V. with notifications on news.

Account

Mn Services Vermogensbeheer B.V. Gilead Sciences, Inc. Transaction History